Trials
Search / Trial NCT06441643

Next Generation Rocklatan

Launched by ALCON RESEARCH · May 29, 2024

Trial Information

Current as of February 19, 2025

Recruiting

Keywords

Glaucoma Iop

ClinConnect Summary

The Next Generation Rocklatan clinical trial is studying two eye drop medications, AR-17043 and PG043, to see how safe they are and how well they can lower eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT). This trial is in its second phase and is currently looking for participants aged between 65 and 74 years. To be eligible for the trial, participants must have a diagnosis of OAG or OHT in both eyes and high eye pressure measurements without current medication. Additionally, they need to have a certain level of vision in the study eye.

If you choose to participate, you will be assessed for your eye health and medical history to ensure you meet the criteria. Throughout the trial, you will receive the study eye drops and regular check-ups to monitor your eye pressure and overall safety. It’s important to note that those currently using more than two eye pressure-lowering medications or who have had previous glaucoma surgery may not be eligible. This study aims to find effective new treatments to help manage eye pressure for individuals with glaucoma and ocular hypertension.

Gender

ALL

Eligibility criteria

  • Stage 1 Key Inclusion Criteria;
  • Diagnosis of OAG or OHT in both eyes.
  • High unmedicated IOP measurements in the study eye as specified in the protocol.
  • Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalent equal to or better than 20/200) in the study eye.
  • Other protocol-specified inclusion criteria may apply.
  • Stage 2 Key Inclusion Criteria:
  • Diagnosis of OAG or OHT in both eyes.
  • High unmedicated IOP measurements in the study eye as specified in the protocol.
  • Corrected visual acuity equal to or better than +0.7 logMAR (Snellen equivalent equal to or better than 20/100) in the study eye.
  • Other protocol-specified inclusion criteria may apply.
  • Stage 1 and Stage 2 Key Exclusion Criteria:
  • Current use of more than 2 ocular hypotensive medications within 30 days (either eye).
  • Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening.
  • Glaucoma other than OAG.
  • Previous glaucoma surgery.
  • Any abnormality preventing reliable measurements.
  • Unable to demonstrate proper eyedrop instillation.
  • Other protocol-specified exclusion criteria may apply.

Trial Officials

Clinical Trial Lead, Pharma

Study Director

Alcon Research, LLC

About Alcon Research

Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.

Locations

Petaluma, California, United States

Inglewood, California, United States

Rochester, New York, United States

Newport Beach, California, United States

Roswell, Georgia, United States

Cranberry Township, Pennsylvania, United States

Lynchburg, Virginia, United States

Maryville, Tennessee, United States

Memphis, Tennessee, United States

Garden Grove, California, United States

Winston Salem, North Carolina, United States

Fort Collins, Colorado, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0